✦ LIBER ✦

MRI-based quantitative assessment of the hippocampal region in very mild to moderate Alzheimer's disease

✍ Scribed by M. Ikeda; H. Tanabe; Y. Nakagawa; H. Kazui; H. Oi; H. Yamazaki; K. Harada; T. Nishimura

Publisher: Springer
Year: 1994
Tongue: English
Weight: 779 KB
Volume: 36
Category: Article
ISSN: 0028-3940
DOI: 10.1007/bf00599184

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The validity and reliability of the Turk

The validity and reliability of the Turkish versii̇on of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild and moderate Alzheimer's disease and normal subjects

✍ H. Mavioglu; M. Gedizlioglu; S. Akyel; T. Aslaner; E. Eser 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB 👁 1 views

## Abstract ## Objectives The cognitive subscale of the Alzheimer's Disease Assesment Scale (ADAS‐Cog) is the most widely used test in clinical trials dealing with Alzheimer's disease (AD). The aim of this study was to investigate the validity and reliability of the Turkish version of ADAS‐Cog. #

Use of donepezil for the treatment of mi

Use of donepezil for the treatment of mild – moderate Alzheimer's disease: an audit of the assessment and treatment of patients in routine clinical practice

✍ Ian Cameron; Stephen Curran; Paul Newton; Duncan Petty; John Wattis 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB 👁 2 views

A multinational, randomised, 12-week stu

A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease

✍ Roy W. Jones; Hilkka Soininen; Klaus Hager; Dag Aarsland; Peter Passmore; Anita 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB 👁 2 views

## Abstract ## Objectives To compare directly, in the same patient cohort, the ease of use and tolerability of donepezil and galantamine in the treatment of Alzheimer's disease (AD), and investigate the effects of both treatments on cognition and activities of daily living (ADL). ## Methods Pati

A multicentre, randomized, double-blind,

A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study

✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 3 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre